BioVie Inc. (BIVI) DCF Valuation

Valoración de DCF Biovie Inc. (BIVI)

US | Healthcare | Biotechnology | NASDAQ
BioVie Inc. (BIVI) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

BioVie Inc. (BIVI) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¿Busca evaluar el valor intrínseco de Biovie Inc.? Nuestra calculadora DCF (BIVI) integra datos del mundo real con características de personalización integrales, lo que le permite refinar sus pronósticos y mejorar sus opciones de inversión.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -2.5 -137.8 -23.7 -45.7 -32.0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .2 .2 .2 .3 .2 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -2.7 -138.0 -23.9 -46.0 -32.2 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash .0 4.5 18.6 33.9 23.8 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 1.3 1.0 .0 .0 3.6 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -5.5 -194.8 -23.9 -46.0 -32.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -4.0 -194.9 -24.7 -45.7 -28.4 -3.6 .0 .0 .0 .0
WACC, % 23.72 23.72 23.72 23.72 23.72 23.72 23.72 23.72 23.72 23.72
PV UFCF
SUM PV UFCF -2.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -3
Net Debt -18
Equity Value 15
Diluted Shares Outstanding, MM 5
Equity Value Per Share 3.28

What You Will Get

  • Real BIVI Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Evaluate various scenarios to assess BioVie Inc.'s future performance.
  • User-Friendly Design: Designed for professionals while remaining easy to navigate for newcomers.

Key Features

  • 🔍 Real-Life BIVI Financials: Pre-filled historical and projected data for BioVie Inc.
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate BioVie’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize BioVie’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • 1. Access the Model: Download and open the Excel file containing BioVie Inc.'s (BIVI) financial data.
  • 2. Adjust Parameters: Modify essential inputs such as growth projections, WACC, and capital investments.
  • 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation scenarios.
  • 5. Present with Assurance: Share professional valuation findings to back your strategic decisions.

Why Choose BioVie Inc. (BIVI)?

  • Innovative Solutions: Focused on developing novel therapies for liver disease and neurodegenerative disorders.
  • Strong Pipeline: A diverse range of clinical-stage products aimed at addressing unmet medical needs.
  • Expert Team: Led by seasoned professionals with extensive experience in biotechnology and pharmaceuticals.
  • Robust Partnerships: Collaborations with leading research institutions and industry partners enhance development capabilities.
  • Commitment to Quality: Adheres to the highest standards of research and development to ensure patient safety and efficacy.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio evaluation of BioVie Inc. (BIVI).
  • Corporate Finance Teams: Examine valuation scenarios to inform strategic decisions within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights to clients regarding BioVie Inc. (BIVI).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Biotech Enthusiasts: Gain insights into how biotech firms like BioVie Inc. (BIVI) are assessed in the market.

What the Template Contains

  • Preloaded BIVI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.